CoChat
Sign Up
Cited by 48

The DOI matches its Crossref record.

Dacarbazine

·2016·Profiles of Drug Substances, Excipients and Related Methodology
DOI 10.1016/bs.podrm.2015.12.002
Open this paper in CoChat — free account

Abstract

Dacarbazine is a cell cycle nonspecific antineoplastic alkylating agent used in the treatment of metastatic malignant melanoma. This chapter contains the descriptions of the drug: nomenclature, formulae, chemical structure, elemental composition, and appearance. The uses and applications of dacarbazine and the methods that were used for its preparation are reported. The methods which were used for the physical characterization of the drug are ionization constant, solubility, X-ray powder diffraction pattern, crystal structure, melting point, and differential scanning calorimetry. The profile contains the spectra of the drug: ultraviolet spectrum, vibrational spectrum, nuclear magnetic resonance spectra, and mass spectrum. The compendial methods of analysis for dacarbazine include the United States Pharmacopeia methods, British Pharmacopeia methods, and International Pharmacopeia methods. Other reported methods that are used for the analysis of the drug are high-performance liquid chromatography, high-performance liquid chromatography-mass spectrometry, and polarography. Metabolism, pharmacokinetics, and stability studies on dacarbazine are also included. Reviews of some analytical methods and physicochemical properties of the drug as well as the most important enzymes that are involved in the prodrug activation are provided. Sixty-four references are listed at the end of this monograph.

Overview

Integrity signals

Registry

Crossref · 10.1016/bs.podrm.2015.12.002

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 59

  1. D’Incan, 2001, Dacarbazine, Ann. Dermatol. Venereol., 128, 517
  2. Eggermont, 2004, Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years, Eur. J. Cancer, 40, 1825, 10.1016/j.ejca.2004.04.030 · DOI
  3. Shealy, 1962, Imidazole I. Coupling reactions of 5-diazoimidazole-4-carboxamide, J. Org. Chem., 27, 2150, 10.1021/jo01053a060 · DOI
  4. Shaw, 1949, A new and convenient synthesis of 4-amino-5-imidazolecarboxamide, J. Biol. Chem., 181, 89, 10.1016/S0021-9258(18)56629-1 · DOI
  5. Iradyan, 2010, Antitumor activity of imidazole derivatives: dacarbazine and the new alkylating agent imidazene (Review), Pharm. Chem. J., 44, 175, 10.1007/s11094-010-0425-6 · DOI
  6. Bei, 2010, Formulation of dacarbazine-loaded cubosomes. Part III. Physicochemical characterization, AAPS PharmSciTech, 11, 1243, 10.1208/s12249-010-9496-7 · DOI
  7. Freeman, 1979, The crystal structure of the anti-tumor agent 5-(3,3-dimethyl-1-triazenyl)imidazole-4-carboxamide (NSC-45388), Acta Crystallogr., B35, 2051, 10.1107/S0567740879008438 · DOI
  8. Edwards, 1974, The crystal structure of the antitumor agent, 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide monohydrate hydrochloride (NSC-45388), J. Am. Chem. Soc., 96, 2593, 10.1021/ja00815a045 · DOI
  9. Freeman, 1979, The crystal structures of two copper(II) complexes of the anti-tumor agent 5-(3,3-dimethyl-1-triazenyl) imidazole-4-carboxamide, Acta Crystallogr., B35, 2045, 10.1107/S0567740879008426 · DOI
  10. Burbank, 1964, A comparison of ω and 2θ scans for integrated intensity measurement, Acta Crystallogr., 17, 434, 10.1107/S0365110X64000950 · DOI
  11. Freeman, 1972, The crystal and molecular structure of bis (glycinato)bis(imidazole)nickel(II), Acta Crystallogr., B28, 2090, 10.1107/S0567740872005588 · DOI
  12. Germain, 1971, The application of phase relationships to complex structures. III. The optimum use of phase relationships, Acta Crystallogr., A27, 368, 10.1107/S0567739471000822 · DOI
  13. 1974, vol. 4, 99
  14. Craven, 1977, The crystal structure of imidazole by neutron diffraction at 20°C and −150°C, Acta Crystallogr., B33, 2585, 10.1107/S0567740877008954 · DOI
  15. Madden, 1972, The crystal structure of orthorhombic form of l-(+)-histidine, Acta Crystallogr., B28, 2377, 10.1107/S0567740872006168 · DOI
  16. Freeman, 1975, The crystal and molecular structure of imidazolium sulfate dihydrate, Acta Crystallogr., B31, 2833, 10.1107/S0567740875008990 · DOI
  17. Gunasekaran, 2008, Density functional theory study of vibrational spectra, and assignment of fundamental modes of dacarbazine, J. Chem. Sci., 120, 315, 10.1007/s12039-008-0054-8 · DOI
  18. Fabrizi, 2012, DESI-MS2: a rapid and innovative method for trace analysis of six cytostatic drugs in health care setting, Anal. Bioanal. Chem., 403, 973, 10.1007/s00216-011-5626-7 · DOI
  19. 2005, vol. 1
  20. Fiore, 1985, Simultaneous determination of dacarbazine, its photolytic degradation product, 2-azahypoxanthine, and the metabolite 5-aminoimidazole-4-carboxamide in plasma and urine by high-performance liquid chromatography, Antimicrob. Agents Chemother., 27, 977, 10.1128/AAC.27.6.977 · DOI
  21. Tate, 1986, Reversed-phase high-performance liquid chromatography of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide and metabolites, J. Chromatogr. Biomed. Appl., 374, 421, 10.1016/S0378-4347(00)83303-4 · DOI
  22. King, 1993, HPLC determination of dacarbazine, doxorubicin and ondansetron mixture in 5% dextrose injection on underivatized silica with an aqueous-organic mobile phase, J. Liq. Chromatogr., 16, 2309, 10.1080/10826079308020988 · DOI
  23. Orsatti, 1995, Electron impact ionization and fast atom bombardment mass spectrometry of some 3,3-dimethyl-l-(isoxasol-3-yl)triazines, a new class of potential anticancer agents, J. Mass Spectrom., 30, 1567, 10.1002/jms.1190301108 · DOI
  24. Haque, 1999, Isocratic determination of dacarbazine and related impurities 2-azahypoxanthine and 5-aminoimidazole-4-carboxamide by HPLC on an avidin protein column, J. Liq. Chromatogr. Relat. Technol., 22, 933, 10.1081/JLC-100101709 · DOI
  25. Safgren, 2001, Validated high-performance liquid chromatographic assay for simultaneous determination of dacarbazine and the plasma metabolites 5-(3-hydroxymethyl-13methyl-1-triazeno)imidazole-4-carboxamide and 5-(3-methyl-1-tiazeno)imidazole-4-carboxamide, J. Chromatogr. B, 754, 91, 10.1016/S0378-4347(00)00586-7 · DOI
  26. Hartinger, 2006, Electrospray ionization mass spectrometric study on the coordination behavior of dacarbazine towards transition metal ions, Polyhedron, 25, 1971, 10.1016/j.poly.2005.12.022 · DOI
  27. Delmas, 2009, Quantitative and qualitative control of cytotoxic preparations by HPLC-UV in a centralized parenteral preparations unit, J. Pharm. Biomed. Anal., 49, 1213, 10.1016/j.jpba.2009.03.007 · DOI
  28. Malik, 2013, Rapid and simultaneous determination of adriamycin, bleomycin, vinblastine and dacarbazine in plasma of Hodgkin's lymphoma patients by a reversed phase HPLC method, J. Chil. Chem. Soc., 58, 1674, 10.4067/S0717-97072013000200006 · DOI
  29. Prasanth, 2014, Stability indicating HPLC method for the determination of dacarbazine in pharmaceutical dosage form, Int. J. Pharm., 4, 5
  30. Chowdhury, 1999, An LC/MS/MS method for the quantitation of MTIC (5-(3-N-methyltriazen-1-yl)-imidazole-4-carboxamide), a bioconversion product of temozolomide, in rat and dog plasma, J. Pharm. Biomed. Anal., 19, 659, 10.1016/S0731-7085(98)00198-8 · DOI
  31. Liu, 2008, Validated hydrophilic interaction LC-MS/MS method for simultaneous quantification of dacarbazine and 5-amino-4-imidazole-caboxamide in human plasma, Talanta, 77, 412, 10.1016/j.talanta.2008.07.004 · DOI
  32. Wasilewska, 1979, Polarographic determination of dacarbazine, Acta Pol. Pharm., 36, 451
  33. Kazemifard, 1979, Comparison of the polarographic and colorimetric methods for the determination of dacarbazine, Arch. Pharm., 312, 573, 10.1002/ardp.19793120703 · DOI
  34. Wasilewska, 1981, Polarographic determination of dacarbazine and 5-amino-4-carbamoylimidazole in human blood and urine, Acta Pol. Pharm., 38, 565
  35. Ordieres, 1987, An electroanalytical study of the anticancer drug dacarbazine, Anal. Chim. Acta, 202, 141, 10.1016/S0003-2670(00)85909-7 · DOI
  36. Rodriguez, 1989, Electrochemical oxidation of dacarbazine and its major metabolite (AIC) on carbon electrodes, Electroanalysis, 1, 529, 10.1002/elan.1140010609 · DOI
  37. Zhang, 2004, A voltammetric study of the effect of gold nanoparticles on the binding of DTIC to DNA bases, Electrochem. Solid-State Lett., 7, J27, 10.1149/1.1758933 · DOI
  38. Zhang, 2005, Specific binding of dacarbazine to DNA bases and oligonucleotides based on gold nanoparticles, J. Nanosci. Nanotechnol., 5, 1245, 10.1166/jnn.2005.216 · DOI
  39. Temerk, 2011, Electrochemical behavior of the anticancer dacarbazine-Cu2+ complex and its analytical applications, Electroanalysis, 23, 1638, 10.1002/elan.201100038 · DOI
  40. Skibba, 1970, N-Demethylation of the antineoplastic agent 4(5)-(3,3-dimethyl-l-triazeno)imidazole-5-(4)-carboxamide by rats and man, Cancer Res., 30, 147
  41. Beal, 1976, Effects of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide and its metabolites on Novikoff hepatoma cells, Cancer Res., 36, 2827
  42. Larsson, 1979, The antitumour agent 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC) inhibits rat liver cAMP phosphodiesterase and amplifies hormone effects in hepatocytes and hepatoma cells, Br. J. Cancer, 40, 768, 10.1038/bjc.1979.259 · DOI
  43. Kolar, 1980, 5-(3-Hydroxymethyl-3-methyl-l-triazeno) imidazole-4-carboxamide is a metabolite of 5-(3,3-dimethyl-l-triazeno)imidazole-4-carboxamide (DIC, DTIC NSC-45388), Cancer Lett., 10, 235, 10.1016/0304-3835(80)90076-2 · DOI
  44. Meer, 1986, In-vivo metabolism and reaction with DNA of the cytostatic agent, 5-(3,3-dimethyl-l-triazeno)imidazole-4-carboxamide (DTIC), Biochem. Pharmacol., 35, 3243, 10.1016/0006-2952(86)90419-3 · DOI
  45. Lewis, 2011, Application of homology modeling to generate CYP1A1 mutants with enhanced activation of the cancer chemotherapeutic prodrug dacarbazine, Mol. Pharmacol., 80, 879, 10.1124/mol.111.072124 · DOI
  46. Yagmagata, 1998, Metabolism of dacarbazine by rat liver microsomes contribution of CYP1A enzymes to dacarbazine N-demethylation, Drug Metab. Dispos., 26, 379
  47. Reid, 1999, Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1, Clin. Cancer Res., 5, 2192
  48. Rooseboom, 2004, Enzyme-catalyzed activation of anticancer prodrugs, Pharmacol. Rev., 56, 53, 10.1124/pr.56.1.3 · DOI
  49. Toft, 2000, In vitro administration of O6-benzylguanine does not influence apoptosis or mutation frequency following DNA damage in the murine intestine but does inhibit P450-dependent activation of dacarbazine, Carcinogenesis, 21, 593, 10.1093/carcin/21.4.593 · DOI
  50. Breithaupt, 1982, Pharmacokinetics of dacarbazine (DTIC) and its metabolite 5-aminoimidazol-4-carboxamide (AIC) following different dose schedules, Cancer Chemother. Pharmacol., 9, 103, 10.1007/BF00265388 · DOI
  51. Buesa, 1991, Clinical pharmacokinetics of high-dose DTIC, Cancer Chemother. Pharmacol., 28, 475, 10.1007/BF00685826 · DOI
  52. Didolkar, 1996, Pharmacokinetics of dacarbazine in the regional perfusion of extremities with melanoma, J. Surg. Oncol., 63, 148, 10.1002/(SICI)1096-9098(199611)63:3<148::AID-JSO4>3.0.CO;2-D · DOI
  53. Rajkumar, 2000, A randomized phase II and pharmacokinetic study of dacarbazine in patients with recurrent glioma, J. Neurooncol., 49, 255, 10.1023/A:1006454427026 · DOI
  54. Benvenuto, 1981, Stability and compatibility of antitumor agents in glass and plastic containers, Am. J. Hosp. Pharm., 38, 1914
  55. Shetty, 1992, Degradation of dacarbazine in aqueous solution, J. Pharm. Biomed. Anal., 10, 675, 10.1016/0731-7085(92)80096-6 · DOI
  56. El-Aatmani, 2002, Stability of dacarbazine in amber glass vial and polyvinyl chloride bags, Am. J. Health Syst. Pharm., 59, 1351, 10.1093/ajhp/59.14.1351 · DOI
  57. Shukla, 1998, Role of bio-metal Fe(III) in anticancer effect of dacarbazine, Indian J. Physiol. Pharmacol., 42, 223
  58. Teimouri, 2013, Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma: a meta-analysis consisting of 1314 patients, Melanoma Res., 23, 381, 10.1097/CMR.0b013e3283649a97 · DOI
  59. Nussbaumer, 2011, Analysis of anticancer drugs: a review, Talanta, 85, 2265, 10.1016/j.talanta.2011.08.034 · DOI

Cited by

Sorted by citations

Metadata

Venue
Profiles of Drug Substances, Excipients and Related Methodology
Publisher
Elsevier
Published
2016
Pages
323-377
ISSN
1871-5125
DOI
10.1016/bs.podrm.2015.12.002
Cited by
48
References
0
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review